Editas Medicine

EDITNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$448.454 M

$2.92 +3.18%

Close of 22 Sept 2026

Revenue

$40.5M

#2797 by revenue

Earnings

-$160.1M

Loss-making

Shares outstanding

153,580,035

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#70Eikon TherapeuticsEIKN$486.4M
#71Kyverna TherapeuticsKYTX$464.4M
#72Editas MedicineEDIT$448.5M
#73Zura BioZURA$432.2M
#74Cabaletta BioCABA$423.9M

What if Editas Medicine were worth as much as…

Open the what-if tool →

Gold $30.2T

$196,861.33

Per share 67,418× higher

Bitcoin $1.74T

$11,340.37

Per share 3,884× higher

Nvidia $5.52T

$35,914.61

Per share 12,300× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Editas Medicine are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.